Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Keywords
COPD, inhaler device, handling
Brief summary
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the world and further increase in its prevalence and mortality has been predicted. Currently, the main long-term treatments are the long-acting beta-2 agonist, indacaterol, salmeterol and the anticholinergic drug, tiotropium and glycopyrronium, used alone or in combination: * long-acting beta-2 agonist with corticosteroid (e.g. salmeterol/fluticasone), * long-acting beta-2 agonist with anticholinergic (e.g. indacatetrol/glycopyrronium). These drugs are delivered to the lung using different inhaler devices such as Breezhaler ®, Handihaler® and Diskus®.
Detailed description
The correct use of inhaler devices is an inclusion criterion in COPD clinical trials. In real life, patients may make many errors using their own inhaler device, which may alter the positive effects observed in clinical trials. The main objective of this study is to describe the handling of inhaler devices (indacaterol-glycopyrronium Breezhaler®, tiotropium Respimat® and salmeterol-fluticasone Diskus®) in patients with COPD. All participants will receive each of the three treatments (Seretide® Diskus® 500/550 μg, Ultibro® Breezhaler® 110/50 μg and Spiriva® Respimat® 2,5 μg). Each treatment will be given daily for one week, followed by a 7-day washout period. On day 1 of each treatment period, the patient will have clinical examination, lung function testing (FEV1) and 2 video recordings: * Video recording #1: inhalation (one puff) without any instruction of use, * Video recording #2: inhalation (one puff) after reading the patient information leaflet. At the end of the visit, the patient will watch a standardized video demonstrating correct inhaler technique. On day 7 of each treatment period, the patient will have clinical examination, lung function testing (FEV1) and 1 video recording of inhaler device use (one puff). 30 days after the last visit, the patient will have a phone contact to collect the adverse events.
Interventions
DRUGSeretide® Diskus® 500/550 μg
Every day during 7 days
DRUGUltibro® Breezhaler® 110/50 μg
Every day during 7 days
DRUGSpiriva® Respimat® 2,5 μg
Every day during 7 days
Sponsors
University Hospital, Bordeaux
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged more than 40 years, * Written informed consent, * Diagnosis of COPD according to international guidelines (GOLD 2012), * Social security or health insurance, * Women of childbearing potential with a very effective contraception according to the Haute Autorité de Santé (HAS) recommendations.
Exclusion criteria
* Previous treatment with Breezhaler®, Diskus® or Respimat® or similar device, * QT ≥ 450 ms, * Contraindications to tiotropium: hypersensitivity to tiotropium, * Contraindications to indacatérol: hypersensitivity to indacatérol, * Contraindications to salmeterol: hypersensitivity to salmeterol, * Contraindications to fluticasone: hypersensitivity to fluticasone, * Contraindications to glycopyrronium: hypersensitivity to glycopyrronium, * COPD exacerbation within 6 weeks before inclusion, * Chronic psychiatric disease, * Medical condition that may affect handling of inhaler devices, * Subject deprived of his/her liberty, * Protected adult, * Subject in exclusion period related to another protocol, * Pregnant or breastfeeding woman
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the presence of at least a major error in the use of the inhalation system, from standardized checklist | Day 7 of each treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of non critical errors from standardized checklist | Day 7 of each treatment | — |
| Number of non device-dependant errors from standardized checklist | Day 7 of each treatment | — |
| Measure of the time necessary for drug administration | Up to day 7 of each treatment | Time in second |
| Measure of Forced Expiratory Volume in 1 second (FEV1) | At baseline and at day 7 | — |
| Collection of adverse events | Up to day 66 | — |
Countries
France
Contacts
STUDY_CHAIRHélène PEYROUZET, Dr
Service Hospitalo-Universitaire de Pharmacologie Médicale
Outcome results
None listed